MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive six ...

AUSTIN (KXAN) — People living with diabetes who depend on insulin now have a different option that doesn’t require needles or pumps to regulate a person’s blood sugar. “People might think you are ...

About Afrezza Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled human insulin indicated to improve glycemic control in adults with diabetes mellitus. Limitations of Use: Not ...

For a drug that many hoped would reach blockbuster status, MannKind Corporation's inhaled insulin Afrezza is off to an awful start. The promise and potential of this medication continues to look huge, ...

MannKind bulls and bears won't have to wait too much longer to see how well the company's inhaled insulin drug, Afrezza, will perform on the market. During MannKind's presentation at the JP Morgan ...